170 related articles for article (PubMed ID: 23490231)
1. M2 receptor activation inhibits cell cycle progression and survival in human glioblastoma cells.
Ferretti M; Fabbiano C; Di Bari M; Conte C; Castigli E; Sciaccaluga M; Ponti D; Ruggieri P; Raco A; Ricordy R; Calogero A; Tata AM
J Cell Mol Med; 2013 Apr; 17(4):552-66. PubMed ID: 23490231
[TBL] [Abstract][Full Text] [Related]
2. M2 muscarinic receptors inhibit cell proliferation in human glioblastoma cell lines.
Ferretti M; Fabbiano C; Di Bari M; Ponti D; Calogero A; Tata AM
Life Sci; 2012 Nov; 91(21-22):1134-7. PubMed ID: 22575825
[TBL] [Abstract][Full Text] [Related]
3. M2muscarinic receptors inhibit cell proliferation and migration in urothelial bladder cancer cells.
Pacini L; De Falco E; Di Bari M; Coccia A; Siciliano C; Ponti D; Pastore AL; Petrozza V; Carbone A; Tata AM; Calogero A
Cancer Biol Ther; 2014; 15(11):1489-98. PubMed ID: 25482946
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic and genotoxic effects mediated by M2 muscarinic receptor activation in human glioblastoma cells.
Di Bari M; Tombolillo V; Conte C; Castigli E; Sciaccaluga M; Iorio E; Carpinelli G; Ricordy R; Fiore M; Degrassi F; Tata AM
Neurochem Int; 2015 Nov; 90():261-70. PubMed ID: 26455407
[TBL] [Abstract][Full Text] [Related]
5. The activation of M2 muscarinic receptor inhibits cell growth and survival in human glioblastoma cancer stem cells.
Alessandrini F; Cristofaro I; Di Bari M; Zasso J; Conti L; Tata AM
Int Immunopharmacol; 2015 Nov; 29(1):105-9. PubMed ID: 26033491
[TBL] [Abstract][Full Text] [Related]
6. Activation of M2 muscarinic acetylcholine receptors by a hybrid agonist enhances cytotoxic effects in GB7 glioblastoma cancer stem cells.
Cristofaro I; Spinello Z; Matera C; Fiore M; Conti L; De Amici M; Dallanoce C; Tata AM
Neurochem Int; 2018 Sep; 118():52-60. PubMed ID: 29702145
[TBL] [Abstract][Full Text] [Related]
7. M2 Muscarinic Receptor Activation Impairs Mitotic Progression and Bipolar Mitotic Spindle Formation in Human Glioblastoma Cell Lines.
Di Bari M; Tombolillo V; Alessandrini F; Guerriero C; Fiore M; Asteriti IA; Castigli E; Sciaccaluga M; Guarguaglini G; Degrassi F; Tata AM
Cells; 2021 Jul; 10(7):. PubMed ID: 34359896
[TBL] [Abstract][Full Text] [Related]
8. The Combined Treatment with Chemotherapeutic Agents and the Dualsteric Muscarinic Agonist Iper-8-Naphthalimide Affects Drug Resistance in Glioblastoma Stem Cells.
Guerriero C; Matera C; Del Bufalo D; De Amici M; Conti L; Dallanoce C; Tata AM
Cells; 2021 Jul; 10(8):. PubMed ID: 34440646
[TBL] [Abstract][Full Text] [Related]
9. The Combination of the M2 Muscarinic Receptor Agonist and Chemotherapy Affects Drug Resistance in Neuroblastoma Cells.
Lucianò AM; Perciballi E; Fiore M; Del Bufalo D; Tata AM
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182656
[TBL] [Abstract][Full Text] [Related]
10. Mir-34a-5p Mediates Cross-Talk between M2 Muscarinic Receptors and Notch-1/EGFR Pathways in U87MG Glioblastoma Cells: Implication in Cell Proliferation.
Di Bari M; Bevilacqua V; De Jaco A; Laneve P; Piovesana R; Trobiani L; Talora C; Caffarelli E; Tata AM
Int J Mol Sci; 2018 May; 19(6):. PubMed ID: 29857516
[TBL] [Abstract][Full Text] [Related]
11. The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype.
Español AJ; Salem A; Di Bari M; Cristofaro I; Sanchez Y; Tata AM; Sales ME
PLoS One; 2020; 15(9):e0226450. PubMed ID: 32911509
[TBL] [Abstract][Full Text] [Related]
12. M2 muscarinic receptor activation regulates Schwann cell differentiation and myelin organization.
Uggenti C; De Stefano ME; Costantino M; Loreti S; Pisano A; Avallone B; Talora C; Magnaghi V; Tata AM
Dev Neurobiol; 2014 Jul; 74(7):676-91. PubMed ID: 24403178
[TBL] [Abstract][Full Text] [Related]
13. Foretinib induces G2/M cell cycle arrest, apoptosis, and invasion in human glioblastoma cells through c-MET inhibition.
Gortany NK; Panahi G; Ghafari H; Shekari M; Ghazi-Khansari M
Cancer Chemother Pharmacol; 2021 Jun; 87(6):827-842. PubMed ID: 33688998
[TBL] [Abstract][Full Text] [Related]
14. Cholinergic activation of phasic activity in the isolated bladder: possible evidence for M3- and M2-dependent components of a motor/sensory system.
Finney SM; Stewart LH; Gillespie JI
BJU Int; 2007 Sep; 100(3):668-78. PubMed ID: 17627783
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of PI3K/Akt signaling mediates proliferation inhibition and G2/M phase arrest induced by andrographolide in human glioblastoma cells.
Li Y; Zhang P; Qiu F; Chen L; Miao C; Li J; Xiao W; Ma E
Life Sci; 2012 Jun; 90(25-26):962-7. PubMed ID: 22634579
[TBL] [Abstract][Full Text] [Related]
16. Effects of platycodin D on proliferation, apoptosis and PI3K/Akt signal pathway of human glioma U251 cells.
Xu C; Sun G; Yuan G; Wang R; Sun X
Molecules; 2014 Dec; 19(12):21411-23. PubMed ID: 25532840
[TBL] [Abstract][Full Text] [Related]
17. Cholinergic modulation of nociceptive responses in vivo and neuropeptide release in vitro at the level of the primary sensory neuron.
Dussor GO; Helesic G; Hargreaves KM; Flores CM
Pain; 2004 Jan; 107(1-2):22-32. PubMed ID: 14715385
[TBL] [Abstract][Full Text] [Related]
18. Oxymatrine induces cell cycle arrest and apoptosis and suppresses the invasion of human glioblastoma cells through the EGFR/PI3K/Akt/mTOR signaling pathway and STAT3.
Dai Z; Wang L; Wang X; Zhao B; Zhao W; Bhardwaj SS; Ye J; Yin Z; Zhang J; Zhao S
Oncol Rep; 2018 Aug; 40(2):867-876. PubMed ID: 29989652
[TBL] [Abstract][Full Text] [Related]
19. M2 receptors exert analgesic action on DRG sensory neurons by negatively modulating VR1 activity.
De Angelis F; Marinelli S; Fioretti B; Catacuzzeno L; Franciolini F; Pavone F; Tata AM
J Cell Physiol; 2014 Jun; 229(6):783-90. PubMed ID: 24166293
[TBL] [Abstract][Full Text] [Related]
20. 2-(2-(2,4-dioxopentan-3-ylidene)hydrazineyl)benzonitrile as novel inhibitor of receptor tyrosine kinase and PI3K/AKT/mTOR signaling pathway in glioblastoma.
Viswanathan A; Kute D; Musa A; Konda Mani S; Sipilä V; Emmert-Streib F; Zubkov FI; Gurbanov AV; Yli-Harja O; Kandhavelu M
Eur J Med Chem; 2019 Mar; 166():291-303. PubMed ID: 30731398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
